Compare ClearPoint Neuro Inc (CLPT) vs Ecolab Inc. (ECL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Ecolab Inc. — how do they compare? ClearPoint Neuro Inc trades at $15.9 (market cap $478.63M), while Ecolab Inc. trades at $272.19 (market cap $75.92B). The key difference: Ecolab Inc. is far larger — about 158.6× ClearPoint Neuro Inc's market cap, and Ecolab Inc. pays a 1.08% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | ECL | |
|---|---|---|
Market Cap | $478.63M | $75.92B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.60 | $308.35 |
52-Week Low | $8.66 | $245.73 |
Enterprise Value | $506.63M | $84.66B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
ECL trades at $271.85, down 0.9% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $327.43, implying significant upside. Recent financials show revenue growth to $16.08B in 2025 and a net income margin of 12.8%, though earnings have been mixed with a Q2 2026 estimate of $2.08 pending. The company's acquisition of CoolIT for $4.75B strengthens its AI cooling portfolio, positioning it for long-term growth in high-tech markets.
The outlook for ECL is positive, supported by strong analyst buy ratings (75.68%) and strategic expansions, but risks include execution of recent acquisitions and cost pressures. The stock's current valuation multiples, such as a P/E of 36.79, suggest premium pricing that requires sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →
